10 August 2026 – Kura Oncology, Inc. announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and… read more.
4 August 2026 – GE HealthCare announced the introduction of the Logiq e family, featuring Logiq e Xi and Logiq e Si, two compact laptop ultrasound systems designed… read more.
Idorsia Ltd announces that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V… read more.
7 August 2026 – Astellas Pharma Inc. confirms it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking approval of… read more.
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.05% to expand the indication for the topical treatment of… read more.
Merck announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV)… read more.
Sanofi K.K. announced that today it submitted an application to Japan’s Ministry of Health, Labour and Welfare for a partial change to the marketing authorization for Dupixent as… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product MenQuadfi…. read more.
Eli Lilly and Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a… read more.
Zevra Therapeutics announced the publication of “Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy” in Molecular Genetics and Metabolism Reports…. read more.
According to the EMA website, on 23 July 2026, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lynavoy, intended… read more.
BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for Voxzogo (vosoritide) for full approval in children with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
